ZG033
/ HankeMab
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 14, 2023
A novel CD137 agonist exhibits potent antitumor efficacy with a good safety profile
(AACR 2023)
- "These data demonstrate that ZG033 is an FcγR crosslinking-dependent CD137 agonist that displays a favorable safety profile and has potential in either mono- or combinational immunotherapies."
Clinical • IO biomarker • Oncology • IFNG • NF-κβ • TNFA
October 06, 2022
ZG033, a novel CD137 agonist, induces superior anti-tumor activity without hepatotoxicity rely on Fc-mediated crosslinking
(SITC 2022)
- "The results in 5-week I.V. repeated-dose (3, 10 and 30 mg/kg) and single-dose toxicity studies (60 and 180 mg/kg) suggested that ZG033 was well tolerated in cynomolgus monkeys with no abnormal hepatic or renal function and hematological index. Conclusions These data demonstrate that ZG033 acts as an FcγR crosslinking-dependent CD137 agonist that displays a favorable safety profile and has potential in either mono- or combinational immunotherapies."
IO biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IFNG • TNFA
1 to 2
Of
2
Go to page
1